» Articles » PMID: 20569095

"A Surviving Myth"--corticosteroids Are Still Considered Ulcerogenic by a Majority of Physicians

Overview
Publisher Informa Healthcare
Specialty Gastroenterology
Date 2010 Jun 24
PMID 20569095
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Evidence does not support an association between systemic corticosteroid use and the development of peptic ulcer disease (PUD) and prophylactic anti-ulcer therapy is not routinely indicated. The aim was to find out the opinion of physicians in the Czech Republic on corticosteroid-induced ulcers.

Materials And Methods: A questionnaire-based study targeting 360 physicians of different specialties (100 from Gastroenterology, 100 from General Practice, 80 from Pneumology/Immunology, and 80 from Neurology/Neurosurgery).

Results: Eighty-two percent of the physicians considered corticosteroids ulcerogenic, 7.5% of the responders considered them ulcerogenic only in patients with a family history of PUD, and 10.3% of the physicians considered corticosteroids non-ulcerogenic. Seventy-five percent of the responders would administer concomitant antisecretory treatment. Sixty-seven percent of the physicians thought that PUD was a frequent complication of corticosteroid therapy. If the ulcerogenic potential of ibuprofen, diclofenac, and prednisone was a subject of the physicians' judgment, a majority (40.5%) considered prednisone to be the most ulcerogenic substance. Thirty percent of gastroenterologists (vs. 1.9% of others; p < 0.001) did not consider corticosteroids to be ulcerogenic; 27.4% (vs. 4.3%; p < 0.01) would not administer an antisecretory prophylaxis routinely.

Conclusions: Although there is no evidence showing an association between PUD and the use of corticosteroids, a majority of physicians consider corticosteroids gastrotoxic. This applies, to a lesser extent, to gastroenterologists. Action should be taken to explode the myth about the gastrotoxicity of corticosteroids and to minimize useless expenses on concomitant prophylaxis.

Citing Articles

Safety of steroids in severe community-acquired pneumonia.

Piedepalumbo F, Motos A, Blasi F, Torres A Eur Respir Rev. 2025; 34(175).

PMID: 39778921 PMC: 11707601. DOI: 10.1183/16000617.0131-2024.


Appropriateness of Antiplatelet Therapy and Proton Pump Inhibitor Prescribing in End-Stage Kidney Disease: A Retrospective Quality Investigation Study.

Che M, Ahmed S, Chan R, Akbari A, Zimmerman D Can J Kidney Health Dis. 2025; 12:20543581241312618.

PMID: 39764378 PMC: 11701909. DOI: 10.1177/20543581241312618.


Impact of connective tissue diseases on inpatient outcomes in gastrointestinal bleeding: insights from a national database analysis.

Johnson A, Piplani S, Akpan E, Zinobia K, Bachan M, Radulovic M Transl Gastroenterol Hepatol. 2024; 9:35.

PMID: 39091649 PMC: 11292097. DOI: 10.21037/tgh-24-5.


Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study.

Liu Y, Zhu X, Li R, Zhang J, Zhang F BMJ Open. 2020; 10(11):e040473.

PMID: 33243802 PMC: 7692833. DOI: 10.1136/bmjopen-2020-040473.


Who Needs Gastroprotection in 2020?.

Kanno T, Moayyedi P Curr Treat Options Gastroenterol. 2020; 18(4):557-573.

PMID: 33199955 PMC: 7656506. DOI: 10.1007/s11938-020-00316-9.